A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE.

Last updated: October 25, 2023
Sponsor: Heron Therapeutics
Overall Status: Completed

Phase

4

Condition

Pain

Acute Pain

Chronic Pain

Treatment

Ibuprofen

HTX-011

Bupivacaine Hydrochloride

Clinical Study ID

NCT06109415
HTX-011-401 (Cohort 1)
  • Ages > 18
  • All Genders

Study Summary

This is a Phase 4, randomized, blinded, active-controlled, multicohort study to evaluate HTX-011 compared with bupivacaine HCl in subjects undergoing Total Shoulder Arthroplasty (TSA) (Cohort 1).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Has American Society of Anesthesiologists (ASA) Physical Status of I, II, or III.
  • Is scheduled to undergo a unilateral Total Shoulder Arthroplasty.

Exclusion

Exclusion Criteria:

  • Is undergoing a revision surgery.
  • Has a known or suspected history of hypersensitivity or clinically significantidiosyncratic reaction to bupivacaine (or other local anesthetics), NSAIDs,acetaminophen, oxycodone, morphine, or hydromorphone.
  • History of severe allergic reaction to aspirin or other NSAIDs, or known history ofsevere gastrointestinal adverse reactions associated with NSAID use.
  • Has taken meloxicam within 10 days prior to the scheduled surgery, or any NSAID within 24 hours prior to the scheduled surgery, with the exception of subjects on low-dose (≤100 mg) daily acetylsalicylic acid for cardioprotection.
  • Opioid use for most days within the last 3 months prior to Screening in the opinion ofthe Investigator.
  • Has been administered immediate-release bupivacaine HCl within 5 days prior to thescheduled surgery, or a modified-release bupivacaine product within 14 days prior tothe scheduled surgery.
  • Has initiated treatment with any of the following medications within 1 month prior tostudy drug administration: selective serotonin reuptake inhibitors, selectivenorepinephrine reuptake inhibitors, gabapentin, pregabalin, duloxetine, orcyclooxygenase-2 inhibitors.
  • Has been administered systemic steroids within 5 half-lives or 10 days prior to thescheduled surgery (whichever is longer).
  • Has a known or suspected history of drug abuse, a positive drug screen (except forcannabinoids) on the day of surgery, or a history of alcohol abuse within the past 5years.
  • Suspected or confirmed active coronavirus disease 2019 (COVID-19) infection.
  • Had a malignancy in the last year, with the exception of nonmetastatic basal cell orsquamous cell carcinoma of the skin or localized carcinoma in situ of the cervix.
  • Has undergone 3 or more surgeries within 12 months, other than for diagnosticprocedures (eg, colonoscopy).
  • Has a body mass index (BMI) >40 kg/m2.

Study Design

Total Participants: 30
Treatment Group(s): 5
Primary Treatment: Ibuprofen
Phase: 4
Study Start date:
October 20, 2021
Estimated Completion Date:
July 29, 2022

Connect with a study center

  • Woodland International Research Group, LLC

    Little Rock, Arkansas 72211
    United States

    Site Not Available

  • Center for Orthopaedic Reconstruction and Excellence

    Jenks, Oklahoma 74037
    United States

    Site Not Available

  • First Surgical Hospital

    Bellaire, Texas 77401
    United States

    Site Not Available

  • Legent Orthopedic Hospital

    Carrollton, Texas 75006
    United States

    Site Not Available

  • JBR Clinical Research

    Salt Lake City, Utah 84107
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.